Akebia Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
/ 
Frequently asked questions
To buy Akebia Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Akebia Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Akebia Therapeutics Inc. is AKBA:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Akebia Therapeutics Inc. has its primary listing on NASDAQ. You can trade Akebia Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Akebia Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Akebia Therapeutics Inc. as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Akebia Therapeutics Inc..